Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHASE-II STUDY OF PYRAZOLOACRIDINE IN PATIENTS WITH ADVANCED COLORECTAL-CARCINOMA
Autore:
ZALUPSKI MM; PHILIP PA; LORUSSO P; SHIELDS AF;
Indirizzi:
WAYNE STATE UNIV,DEPT MED,DIV HEMATOL & ONCOL,KARMANOS CANC CTR DETROIT MI 48201
Titolo Testata:
Cancer chemotherapy and pharmacology
fascicolo: 3, volume: 40, anno: 1997,
pagine: 225 - 227
SICI:
0344-5704(1997)40:3<225:PSOPIP>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Keywords:
PYRAZOLOACRIDINE; COLORECTAL CANCER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
9
Recensione:
Indirizzi per estratti:
Citazione:
M.M. Zalupski et al., "PHASE-II STUDY OF PYRAZOLOACRIDINE IN PATIENTS WITH ADVANCED COLORECTAL-CARCINOMA", Cancer chemotherapy and pharmacology, 40(3), 1997, pp. 225-227

Abstract

Purpose: Pyrazoloacridine (PZA) is an acridine derivative selected for clinical development because of broad preclinical antitumor activityand solid tumor selectivity. Phase I evaluations with PZA have demonstrated predictable toxicity and suggested clinical efficacy. A phase II trial in patients with previously untreated advanced colorectal cancer was conducted. Methods: PZA was administered at a dose of 750 mg/m(2) intravenously over 3 h every 21 days to patients who received a total of 31 courses of PZA. Results: In 15 patients evaluable for response, no responses were observed (0% response rate, 95% confidence interval 0-22%). Toxicity to PZA consisted of myelosuppression and neurotoxicity that was treatment-limiting in several instances. Conclusion: PZAat this dose and schedule of administration is inactive in patients with colorectal cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/09/20 alle ore 10:25:15